{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T13:12:07Z","timestamp":1771593127005,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11864-025-01375-9","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:33:25Z","timestamp":1771590805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Endocrinologic Toxicities of Cancer Therapy: Evolving Challenges and Multidisciplinary Approaches"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4320-222X","authenticated-orcid":false,"given":"Tugce","family":"Akcan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2883-4017","authenticated-orcid":false,"given":"Angela N.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7428-6561","authenticated-orcid":false,"given":"Afreen Idris","family":"Shariff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"1375_CR1","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1210\/clinem\/dgac689","volume":"108","author":"JJ Wright","year":"2023","unstructured":"Wright JJ, Johnson DB. Approach to the patient with immune checkpoint Inhibitor-Associated endocrine dysfunction. J Clin Endocrinol Metab. 2023;108:1514\u201325. https:\/\/doi.org\/10.1210\/clinem\/dgac689.","journal-title":"J Clin Endocrinol Metab"},{"key":"1375_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021;17:389\u201399. https:\/\/doi.org\/10.1038\/s41574-021-00484-3.","journal-title":"Nat Rev Endocrinol"},{"key":"1375_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","volume":"40","author":"L-S Chang","year":"2019","unstructured":"Chang L-S, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019;40:17\u201365. https:\/\/doi.org\/10.1210\/er.2018-00006.","journal-title":"Endocr Rev"},{"key":"1375_CR4","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol Wolters Kluwer. 2021;39:4073\u2013126. https:\/\/doi.org\/10.1200\/JCO.21.01440.","journal-title":"J Clin Oncol Wolters Kluwer"},{"key":"1375_CR5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/cancers15010246","volume":"15","author":"CC Spagnolo","year":"2022","unstructured":"Spagnolo CC, Giuffrida G, Cannav\u00f2 S, Franchina T, Silvestris N, Ruggeri RM, et al. Management of endocrine and metabolic toxicities of Immune-Checkpoint inhibitors: from clinical studies to a Real-Life scenario. Cancers. 2022;15:246. https:\/\/doi.org\/10.3390\/cancers15010246.","journal-title":"Cancers"},{"key":"1375_CR6","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40618-018-0984-z","volume":"42","author":"RM Ruggeri","year":"2019","unstructured":"Ruggeri RM, Campenn\u00ec A, Giuffrida G, Trimboli P, Giovanella L, Trimarchi F, et al. Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know) J Endocrinol Invest 2019;42:745\u201356. . https:\/\/doi.org\/10.1007\/s40618-018-0984-z.","journal-title":"J Endocrinol Invest"},{"key":"1375_CR7","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1089\/jpm.2022.0204","volume":"25","author":"MN Ferreira","year":"2022","unstructured":"Ferreira MN, Rao M, Kamal AH, Shariff A. Top ten tips palliative care clinicians should know about managing Immune-Mediated endocrine toxicities in cancer. J Palliat Med. 2022;25:1715\u201320. https:\/\/doi.org\/10.1089\/jpm.2022.0204.","journal-title":"J Palliat Med"},{"key":"1375_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.eprac.2022.04.010","volume":"28","author":"KCJ Yuen","year":"2022","unstructured":"Yuen KCJ, Samson SL, Bancos I, Gosmanov AR, Jasim S, Fecher LA, et al. American association of clinical endocrinology disease state clinical review: evaluation and management of immune checkpoint Inhibitor-Mediated endocrinopathies: A practical Case-Based clinical approach. Endocr Pract Elsevier. 2022;28:719\u201331. https:\/\/doi.org\/10.1016\/j.eprac.2022.04.010.","journal-title":"Endocr Pract Elsevier"},{"key":"1375_CR9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3390\/cancers15020375","volume":"15","author":"A Shalit","year":"2023","unstructured":"Shalit A, Sarantis P, Koustas E, Trifylli E-M, Matthaios D, Karamouzis MV. Predictive biomarkers for immune-Related endocrinopathies following immune checkpoint inhibitors treatment. Cancers. 2023;15:375. https:\/\/doi.org\/10.3390\/cancers15020375.","journal-title":"Cancers"},{"key":"1375_CR10","unstructured":"2025 ICD-10-CM, Diagnosis Code T. 45.AX5A: Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, initial encounter [Internet]. [cited 2025 Sept 12]. https:\/\/www.icd10data.com\/ICD10CM\/Codes\/S00-T88\/T36-T50\/T45-\/T45.AX5A. Accessed 12 Sept 2025."},{"key":"1375_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jpainsymman.2020.07.037","volume":"61","author":"M Al Maqbali","year":"2021","unstructured":"Al Maqbali M, Al Sinani M, Al Naamani Z, Al Badi K, Tanash MI. Prevalence of fatigue in patients with cancer: A systematic review and Meta-Analysis. J Pain Symptom Manage. 2021;61:167\u2013e18914. https:\/\/doi.org\/10.1016\/j.jpainsymman.2020.07.037.","journal-title":"J Pain Symptom Manage"},{"key":"1375_CR12","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1200\/JCO.24.00541","volume":"42","author":"JE Bower","year":"2024","unstructured":"Bower JE, Lacchetti C, Alici Y, Barton DL, Bruner D, Canin BE, et al. Management of fatigue in adult survivors of cancer: ASCO\u2013Society for integrative oncology guideline update. J Clin Oncol Wolters Kluwer. 2024;42:2456\u201387. https:\/\/doi.org\/10.1200\/JCO.24.00541.","journal-title":"J Clin Oncol Wolters Kluwer"},{"key":"1375_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejca.2022.08.029","volume":"176","author":"TU Schulz","year":"2022","unstructured":"Schulz TU, Zierold S, Sachse MM, Pesch G, Tomsitz D, Schilbach K, et al. Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: prevalence and impact on patients\u2019 health-related quality of life. Eur J Cancer Oxf Engl 1990. 2022;176:88\u201399. https:\/\/doi.org\/10.1016\/j.ejca.2022.08.029.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"1375_CR14","doi-asserted-by":"publisher","unstructured":"Bade BC, Faiz SA, Ha DM, Tan M, Barton-Burke M, Cheville AL et al. Cancer-related fatigue in lung cancer: A research agenda: an official American thoracic society research statement. Am J Respir Crit Care Med 207:e6\u201328. https:\/\/doi.org\/10.1164\/rccm.202210-1963ST","DOI":"10.1164\/rccm.202210-1963ST"},{"key":"1375_CR15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41598-024-84488-9","volume":"15","author":"Y Iwamoto","year":"2025","unstructured":"Iwamoto Y, Kimura T, Dan K, Iwamoto H, Sanada J, Fushimi Y, et al. Clinical outcomes of endocrine and other disorders induced by immune checkpoint inhibitors in Japanese patients. Sci Rep Nat Publishing Group. 2025;15:390. https:\/\/doi.org\/10.1038\/s41598-024-84488-9.","journal-title":"Sci Rep Nat Publishing Group"},{"key":"1375_CR16","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EC-18-0068","volume":"7","author":"CE Higham","year":"2018","unstructured":"Higham CE, Olsson-Brown A, Carroll P, Cooksley T, Larkin J, Lorigan P, SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE, et al. Acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect. 2018;7:G1\u20137. https:\/\/doi.org\/10.1530\/EC-18-0068.","journal-title":"Endocr Connect"},{"key":"1375_CR17","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1056\/NEJMoa1000678","volume":"363","author":"JS Temel","year":"2010","unstructured":"Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1000678.","journal-title":"N Engl J Med"},{"key":"1375_CR18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1200\/JCO.2016.70.1474","volume":"35","author":"BR Ferrell","year":"2017","unstructured":"Ferrell BR, Temel JS, Temin S, Alesi ER, Balboni TA, Basch EM, et al. Integration of palliative care into standard oncology care: American society of clinical oncology clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:96\u2013112. https:\/\/doi.org\/10.1200\/JCO.2016.70.1474.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1375_CR19","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.diabres.2017.09.018","volume":"143","author":"T Dunning","year":"2018","unstructured":"Dunning T, Martin P. Palliative and end of life care of people with diabetes: Issues, challenges and strategies. Diabetes Res Clin Pract. 2018;143:454\u201363. https:\/\/doi.org\/10.1016\/j.diabres.2017.09.018.","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01375-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01375-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01375-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:33:26Z","timestamp":1771590806000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01375-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1375"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01375-9","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"20 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"All authors approve the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}